Archives of Toxicology

, Volume 69, Issue 7, pp 491–497 | Cite as

Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid

  • Mary W. Wilson
  • L. Travis Lay
  • Ching K. Chow
  • Hsin -Hsiung Tai
  • Larry W. Robertson
  • Howard P. Glauert
Original Investigation


Several hypolipidemic drugs, plasticizers, and other chemicals induce hepatic peroxisome proliferation and hepatocellular carcinomas in rodents. These agents induce and promote hepatocarcinogenesis by unknown mechanisms, since most studies have not found them to be genotoxic. Peroxisome proliferators increase the expression of several genes, including those for the enzymes of the peroxisomal β-oxidation path-way and the cytochrome P-450 4A family, which metabolize lipids, including eicosanoids and their precursor fatty acids. The peroxisome proliferators ciprofibrate and perfluorodecanoic acid (PFDA) were therefore examined for their ability to alter hepatic eicosanoid concentrations. Rats received injections of 3 or 10 mg PFDA/kg body weight every 14 days or were fed 0.01% ciprofibrate for 10 days, 24 days, 6 weeks, 26 weeks, or 54 weeks. The activity of the peroxisomal enzyme fatty acyl CoA oxidase was significantly increased by both ciprofibrate and PFDA at all times. Hepatic concentrations of prostaglandins E2 and F (PGE2, PGF) thromboxane B2 (TXB2), and leukotriene C4 (LTC4) were measured by immunoassay. Concentrations of PGE2, PGF, and TXB2 were decreased in livers of rats receiving ciprofibrate or PFDA compared to livers of control rats, with ciprofibrate exerting a greater effect than PFDA at the doses used. Hepatic LTC4 concentrations were significantly increased by ciprofibrate at 10 days and PFDA at 54 weeks, and significantly decreased by PFDA at 26 weeks. These alterations in eicosanoid concentrations may be important in the natural history of peroxisome proliferator-induced hepatocarcinogenesis.

Key words

Ciprofibrate Perfluorodecanoic acid Eicosanoids Peroxisome 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bains SK, Gardiner SM, Mannweiler K, Gillett D, Gibson GG (1985) Immunochemical study on the contribution of hypolipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid. Biochem Pharmacol 34: 3221–3229PubMedCrossRefGoogle Scholar
  2. Beer DG, Pitot HC (1987) Biological markers characterizing the development of preneoplastic and neoplastic lesions in rodent liver. Arch Toxicol Suppl. 10: 68–80PubMedGoogle Scholar
  3. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand HJ (1993) Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem Toxicol 31: 857–907PubMedCrossRefGoogle Scholar
  4. Borges T, Glauert HP, Chen L-C, Chow CK, Robertson LW (1990) Effect of the peroxisome proliferator perfluorodecanoic acid on growth and lipid metabolism in Sprague Dawley rats fed three dietary levels of selenium. Arch Toxicol 64: 26–30PubMedCrossRefGoogle Scholar
  5. Borges T, Robertson LW, Peterson RE, Glauert HP (1992) Doserelated effects of perfluorodecanoic acid on growth, feed intake and hepatic peroxisomal beta-oxidation. Arch Toxicol 66: 18–22PubMedCrossRefGoogle Scholar
  6. Borges T, Glauert HP, Robertson LW (1993a) Perfluorodecanoic acid noncompetitively inhibits the peroxisomal enzymes enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase. Toxicol Appl Pharmacol 118: 8–15PubMedCrossRefGoogle Scholar
  7. Borges T, Peterson RE, Pitot HC, Robertson LW, Glauert HP (1993b) Effect of the peroxisome proliferator perfluorodecanoic acid on the promotion of 2-stage hepatocarcinogenesis in rats. Cancer Lett 72: 111–120PubMedCrossRefGoogle Scholar
  8. Brass EP, Ruff LJ (1991) Effect of clofibrate treatment on hepatic prostaglandin catabolism and action. J Pharmacol Exp Ther 257: 1034–1038PubMedGoogle Scholar
  9. Capdevila JH, Falck JR, Estabrook RW (1992) Cytochrome-P450 and the arachidonate cascade. FASEB J 6: 731–736PubMedGoogle Scholar
  10. Cayen MN (1983) Metabolism and pharmacokinetics of antihyperlipidaemic agents. Prog Drug Metab 7: 173–227Google Scholar
  11. Denda A, Ura H, Tsujiuchi T, Tsutsumi M, Eimoto H, Takashima Y, Kitazawa S, Kinugasa T, Konishi Y (1989) Possible involvement of arachidonic acid metabolism in phenobarbital promotion of hepatocarcinogenesis. Carcinogenesis 10: 1929–1935PubMedCrossRefGoogle Scholar
  12. Diczfalusy U, Alexson SEH (1990) Identification of metabolites from peroxisomal β-oxidation of prostaglandins. J Lipid Res 31: 307–314PubMedGoogle Scholar
  13. Diczfalusy U, Vesterqvist O, Kase BF, Lund E, Alexson SEH (1993) Peroxisomal chain-shortening of thromboxane B2—evidence for impaired degradation of thromboxane B2 in Zellweger syndrome. J Lipid Res 34: 1107–1113PubMedGoogle Scholar
  14. Fischer SM, Fürstenberger G, Marks F, Slaga TJ (1987) Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: a comparison between SENCAR and NMRI mice. Cancer Res 47: 3174–3179PubMedGoogle Scholar
  15. Foxworthy PS, Perry DN, Eacho PI, (1993) Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs. Toxicol Appl Pharmacol 118: 271–274PubMedCrossRefGoogle Scholar
  16. George ME, Andersen ME (1986) Toxic effects of nonadecafluoro-,n-decanoic acid in rats. Toxicol Appl Pharmacol 85: 169–180PubMedCrossRefGoogle Scholar
  17. Gill JL (1978) Design and Analysis of Experiments in the Animal and Medical Sciences, Volume 1. Iowa State University Press, Ames, IowaGoogle Scholar
  18. Glauert HP, Beaty MM, Clark TD, Greenwell WS, Tatum V, Chen LC, Borges T, Clark TL, Srinivasan SR, Chow CK (1990) Effect of dietary vitamin E on the development of altered hepatic foci and hepatic tumors induced by the peroxisome proliferator ciprofibrate. J Cancer Res Clin Oncol 116: 351–356PubMedCrossRefGoogle Scholar
  19. Gronn M, Christensen E, Hagve TA, Christophersen BO (1992) Effects of clofibrate feeding on essential fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1123: 170–176PubMedGoogle Scholar
  20. Gupta C, Banks M, Shinozuka H (1989) Elevated levels of prostaglandin E2 in the liver of rats fed a choline deficient diet: possible involvement in liver tumor promotion. Cancer Lett 46: 129–135PubMedCrossRefGoogle Scholar
  21. Hawkins JM, Jones WE, Bonner FW, Gibson GG (1987) The effect of peroxisome proliferators on microsomal peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab Rev 18: 441–515PubMedCrossRefGoogle Scholar
  22. Hendrich S, Krueger SK, Chen HW, Cook L (1991) Phenobarbital increases rat hepatic prostaglandin F, glutathione-S-transferase activity, and oxidative stress. Prostaglandins Leukotrienes Essential Fatty Acids 42: 45–50CrossRefGoogle Scholar
  23. Huwyler J, Jedlitschky G, Keppler D, Gut J (1992) Halothane metabolism—impairment of hepatic omega-oxidation of leukotrienes in vivo and in vitro. Eur J Biochem 206: 869–879PubMedCrossRefGoogle Scholar
  24. Jedlitschky G, Huber M, Völkl A, Müller M, Leier I, Müller J, Lehmann WD, Fahimi HD, Keppler D (1991) Peroxisomal degradation of leukotrienes by beta-oxidation from the omegaend. J Biol Chem 266: 24763–24772PubMedGoogle Scholar
  25. Kawashima Y, Hirose A, Kozuka H (1984) Modification by clofibric acid of acyl composition of glycolipids in rat liver. Possible involvement of fatty acid chain elongation and desaturation. Biochim Biophys Acta 795: 543–551PubMedGoogle Scholar
  26. Kawashima Y, Nishizawa H, Kozuka H (1992) Reduction by clofibric acid of serum arachidonic acid in rats—effect on the acyl composition of renal phospholipids. Biochem Pharmacol 43: 2321–2326PubMedCrossRefGoogle Scholar
  27. Kupfer D (1980) Endogenous substrates of monooxygenases, fatty acids and prostaglandins. Pharmacol Ther 11: 469–496PubMedCrossRefGoogle Scholar
  28. Lalwani ND, Reddy MK, Qureshi SA, Sirtori CR, Abiko Y, Reddy JK (1982) Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver. Hum Toxicol 2: 27–48CrossRefGoogle Scholar
  29. Lee PPH, Ip MM (1992) Regulation of proliferation of rat mammary tumor cells by inhibitors of cyclooxygenase and lipoxygenase. Prostaglandins Leukotrienes Essential Fatty Acids 45: 21–31CrossRefGoogle Scholar
  30. Lock EA, Mitchell AM, Elcombe CR (1989) Biochemical mechanisms of induction of hepatic peroxisome proliferation. Annu Rev Pharmacol Toxicol 29: 145–163PubMedCrossRefGoogle Scholar
  31. Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575–5589PubMedGoogle Scholar
  32. Olson CT, Andersen ME (1983) The acute toxicity of perfluorooctanoic and perfluorodecanoic acids in male rats and the effect on tissue fats. Toxicol Appl Pharmacol 70: 362–372PubMedCrossRefGoogle Scholar
  33. Poosch MS, Yamazaki RK (1986) Determination of peroxisomal fatty acyl-CoA oxidase activity using a lauroyl-CoA-based fluorometric assay. Biochim Biophys Acta 884: 585–593PubMedGoogle Scholar
  34. Powell WS (1982) Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol 86: 467–477PubMedCrossRefGoogle Scholar
  35. Pradelles P, Grassi J, Maclouf J (1985) Enzyme immunoassay of eicosanoids using acetylcholinesterase as label: an alternative to radioimmunoassay. Anal Chem 57: 1170–1173PubMedCrossRefGoogle Scholar
  36. Reddy JK, Lalwani ND (1983) Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 12: 1–58CrossRefGoogle Scholar
  37. Skouteris GG, Ord MG, Stocken LA (1988) Regulation of the proliferation of primary rat hepatocytes by eicosanoids. J Cell Physiol 135: 516–520PubMedCrossRefGoogle Scholar
  38. Tai HH, Yuan B (1978) Development of radioimmunoassay for thromboxane B2. Anal Biochem 87: 343–349PubMedCrossRefGoogle Scholar
  39. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K, Hayashi Y (1990) Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Carcino-genesis 11: 393–395CrossRefGoogle Scholar
  40. Tang Q, Denda A, Tsujiuchi T, Tsutsumi M, Amanuma T, Murata Y, Maruyama H, Konishi Y (1993) Inhibitory effects of inhibitors of arachidonic acid metabolism on the evolution of rat liver preneoplastic foci into nodules and hepatocellular carcinomas with or without phenobarbital exposure. Jpn J Cancer Res 84: 120–127PubMedGoogle Scholar
  41. Vamecq J, Draye JP (1987) Interactions between the omega-and β-oxidations of fatty acids. J Biochem 102: 225–234PubMedGoogle Scholar
  42. Vamecq J, Draye JP (1989) Peroxisomal and mitochondrial β-oxidation of monocarboxyl-CoA, omega-hydroxymonocarboxylyl-CoA and dicarboxylyl-CoA esters in tissues from untreated and clofibrate-treated rats. J Biochem 106: 216–222PubMedGoogle Scholar
  43. Vanden Heuvel JP, Kuslikis BI, Van Rafelghem MJ, Peterson RE (1991) Disposition of perfluorodecanoic acid in male and female rats. Toxicol Appl Pharmacol 107: 450–459CrossRefGoogle Scholar
  44. Wickremasinghe RG (1988) The role of prostaglandin in the regulation of cell proliferation. Prostaglandins Leukotrienes Essential Fatty Acids 31: 171–179Google Scholar
  45. Willis AL (1987) The eicosanoids: an introduction and an overview. In: Willis AL (ed) CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids, Volume 1. Chemical and Biochemical Aspects. CRC Press, Boca Raton, Fla. pp 3–46Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • Mary W. Wilson
    • 1
  • L. Travis Lay
    • 1
  • Ching K. Chow
    • 1
    • 2
  • Hsin -Hsiung Tai
    • 3
  • Larry W. Robertson
    • 2
  • Howard P. Glauert
    • 1
    • 2
  1. 1.Department of Nutrition and Food ScienceUniversity of KentuckyLexingtonUSA
  2. 2.Graduate Center for ToxicologyUniversity of KentuckyLexingtonUSA
  3. 3.College of PharmacyUniversity of KentuckyLexingtonUSA

Personalised recommendations